Open AccessSeven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation
Author(s) -
Jung Wook Lee,
Su Jin Kim,
Cheol Woong Choi,
Hyeong-Jin Kim,
Dae Hwan Kang,
Hyung Wook Kim,
Su Bum Park,
Hyeong Seok Nam,
Dae Gon Ryu
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000026133
Subject(s) - medicine , point mutation , 23s ribosomal rna , helicobacter pylori , clarithromycin , adverse effect , gastroenterology , mutation , genetics , gene , ribosome , rna , biology
Tailored therapy based on dual priming oligonucleotide-based polymerase chain reaction (DPO-PCR) can be considered an alternative to overcome the low eradication rate in high clarithromycin-resistance areas. The triple therapy (TT) duration of the tailored approach in most studies was 7 days for patients without point mutation. However, recent western guidelines have recommended a treatment duration of 14 days. The aim of this study was to compare the success rate of 7 and 14 days of TT for eradicating Helicobacter pylori without point mutation, as determined by DPO-PCR. Between Feb 2016 and Feb 2019, medical records of patients who underwent DPO-PCR were reviewed. Patients without point mutation as determined by DPO-PCR were enrolled in this study. The eradication success rate and adverse events were evaluated. A total of 366 patients without A2142G and A2143G point mutation were enrolled. The success rates of 7-day and 14-day TT were 88.4% (168/190) and 85.9% (151/176) by intention to treat analysis ( P = .453) and 90.8% (168/185) and 90.4% (151/167) by per-protocol analysis ( P = .900), respectively. The adverse event rates showed no significant difference between the 2 groups. In patients without point mutation based on DPO-PCR results, 7-day TT is as effective as 14-day TT. Therefore, 7 days may be considered as a cost-effective treatment duration in Korea.